These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 27180831)

  • 41. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
    Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
    J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice.
    Hirata S; Li W; Kubo S; Fukuyo S; Mizuno Y; Hanami K; Sawamukai N; Yamaoka K; Saito K; Defranoux NA; Tanaka Y
    Mod Rheumatol; 2016 Nov; 26(6):850-856. PubMed ID: 26873570
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-α antagonist therapies.
    Sarsour K; Greenberg J; Johnston JA; Nelson DR; O'Brien LA; Oddoux C; Ostrer H; Pearlman A; Reed G
    Clin Exp Rheumatol; 2013; 31(2):189-94. PubMed ID: 23294992
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.
    Kastbom A; Bratt J; Ernestam S; Lampa J; Padyukov L; Söderkvist P; Skogh T
    Arthritis Rheum; 2007 Feb; 56(2):448-52. PubMed ID: 17265480
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discrepancies between the EULAR response criteria and the NICE guidelines for continuation of anti-TNF therapy in RA: a cause for concern?
    Jerram S; Butt S; Gadsby K; Deighton C
    Rheumatology (Oxford); 2008 Feb; 47(2):180-2. PubMed ID: 18160419
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of rheumatoid arthritis risk alleles with response to anti-TNF biologics: results from the CORRONA registry and meta-analysis.
    Pappas DA; Oh C; Plenge RM; Kremer JM; Greenberg JD
    Inflammation; 2013 Apr; 36(2):279-84. PubMed ID: 23007924
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor.
    Farutin V; Prod'homme T; McConnell K; Washburn N; Halvey P; Etzel CJ; Guess J; Duffner J; Getchell K; Meccariello R; Gutierrez B; Honan C; Zhao G; Cilfone NA; Gunay NS; Hillson JL; DeLuca DS; Saunders KC; Pappas DA; Greenberg JD; Kremer JM; Manning AM; Ling LE; Capila I
    Arthritis Res Ther; 2019 Oct; 21(1):216. PubMed ID: 31647025
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
    Matsudaira R; Tamura N; Sekiya F; Ogasawara M; Yamanaka K; Takasaki Y
    J Rheumatol; 2011 Nov; 38(11):2346-54. PubMed ID: 21965648
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden.
    Raaschou P; Simard JF; Holmqvist M; Askling J;
    BMJ; 2013 Apr; 346():f1939. PubMed ID: 23568792
    [TBL] [Abstract][Full Text] [Related]  

  • 50. TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis.
    O'Rielly DD; Roslin NM; Beyene J; Pope A; Rahman P
    Pharmacogenomics J; 2009 Jun; 9(3):161-7. PubMed ID: 19365401
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Changes in MiRNA-5196 Expression as a Potential Biomarker of Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis Patients.
    Ciechomska M; Bonek K; Merdas M; Zarecki P; Swierkot J; Gluszko P; Bogunia-Kubik K; Maslinski W
    Arch Immunol Ther Exp (Warsz); 2018 Oct; 66(5):389-397. PubMed ID: 29744553
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SLC04A1, SLC22A2 and SLC28A2 variants not related to methotrexate efficacy or toxicity in rheumatoid arthritis patients.
    Eektimmerman F; Swen JJ; Böhringer S; Aslibekyan S; Allaart CF; Guchelaar HJ
    Pharmacogenomics; 2018 May; 19(7):613-619. PubMed ID: 29701127
    [TBL] [Abstract][Full Text] [Related]  

  • 53. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis.
    Miceli-Richard C; Comets E; Verstuyft C; Tamouza R; Loiseau P; Ravaud P; Kupper H; Becquemont L; Charron D; Mariette X
    Ann Rheum Dis; 2008 Apr; 67(4):478-84. PubMed ID: 17673491
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.
    Fernández-Nebro A; Irigoyen MV; Ureña I; Belmonte-López MA; Coret V; Jiménez-Núñez FG; Díaz-Cordovés G; López-Lasanta MA; Ponce A; Rodríguez-Pérez M; Calero E; González-Santos P
    J Rheumatol; 2007 Dec; 34(12):2334-42. PubMed ID: 17985409
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Variations in the metabolome in response to disease activity of rheumatoid arthritis.
    Tatar Z; Migne C; Petera M; Gaudin P; Lequerre T; Marotte H; Tebib J; Pujos Guillot E; Soubrier M
    BMC Musculoskelet Disord; 2016 Aug; 17(1):353. PubMed ID: 27549132
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure.
    Solau-Gervais E; Prudhomme C; Philippe P; Duhamel A; Dupont-Créteur C; Legrand JL; Houvenagel E; Flipo RM
    Joint Bone Spine; 2012 May; 79(3):281-4. PubMed ID: 21724444
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.
    Jamnitski A; Bartelds GM; Nurmohamed MT; van Schouwenburg PA; van Schaardenburg D; Stapel SO; Dijkmans BA; Aarden L; Wolbink GJ
    Ann Rheum Dis; 2011 Feb; 70(2):284-8. PubMed ID: 21068090
    [TBL] [Abstract][Full Text] [Related]  

  • 59. TNFRII polymorphism is associated with response to TNF blockers in rheumatoid arthritis patients seronegative for ACPA.
    Pers YM; Cadart D; Rittore C; Ravel P; Daïen V; Fabre S; Jorgensen C; Touitou I
    Joint Bone Spine; 2014 Jul; 81(4):370-2. PubMed ID: 24462126
    [No Abstract]   [Full Text] [Related]  

  • 60. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug.
    Söderlin MK; Petersson IF; Geborek P
    Scand J Rheumatol; 2012 Feb; 41(1):1-9. PubMed ID: 22118371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.